Printer Friendly

SPI'S MEXICAN SUBSIDIARY ANNOUNCES $5 MILLION EXPANSION

SPI'S MEXICAN SUBSIDIARY ANNOUNCES $5 MILLION EXPANSION
    COSTA MESA, Calif., Oct. 1 /PRNewswire/ -- SPI Pharmaceuticals Inc. (AMEX: SPI) today announced it is investing $5 million to update machinery and technologies at its factories in Mexico City to support long-term business expansion in Latin America.
    One of the largest U.S. pharmaceutical companies operating in Mexico, SPI employs approximately 800 workers in the country and manufactures, markets and distributes a broad range of prescription products, including anti-infectives and injectable multivitamins.
    SPI's sales in Mexico last year topped $45 million.  It is in the top 20 in market share out of more than 350 pharmaceutical companies in the country of 85 million people.
    In the second quarter, SPI launched several new products in Mexico, including Supra (lidamidine-Hcl), used to treat colitis, and Flouravit (fluor), a fluoride supplement in tablet form.  Fluoride is not added to the water system in some Mexican cities.
    Earlier this week, SPI announced that the Mexican government has authorized use of its antiviral cream Virazole (ribavirin 7.5 percent) to treat herpes zoster and herpes genitalis.
    In addition to Mexico, SPI currently sells products throughout Central America and the Dominican Republic.
    SPI Pharmaceuticals Inc., headquartered in Costa Mesa, manufactures, markets and distributes 600 prescription and nonprescription pharmaceuticals in more than 60 countries, including the United States, Canada, Western and Eastern Europe, and the Far East.
    -0-             10/01/92
    CONTACT:  Paul Knopick of SPI Pharmaceuticals, 714-545-0100, ext. 2465
    (SPI) CO:  SPI PHARMACEUTICALS INC. IN:  MTC ST:  CA -- LA004 -- X902  10/01/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 1, 1992
Words:254
Previous Article:KEITHLEY INSTALLS ONE OF ONLY NINE U.S. JOSEPHSON JUNCTION VOLTAGE STANDARDS
Next Article:INTERNATIONAL TECHNOLOGY CORP. AWARDED TIMES BEACH THERMAL REMEDIATION PROJECT BY EBASCO
Topics:


Related Articles
ICN PHARMACEUTICALS OPENS NEW SPANISH PLANT AS PART OF EUROPEAN EXPANSION
ICN PHARMACEUTICALS REPORTS RECORD FIRST QUARTER SALES AND EARNINGS; LONG-TERM LIABILITIES REDUCED BY $40 MILLION
SPI PRESIDENT TELLS SPANISH TRADE DELEGATION COMPANY GROWTH LINKED TO EUROPEAN EXPANSION
SPI PHARMACEUTICALS REPORTS RECORD SECOND QUARTER SALES AND NET INCOME
SPI PHARMACEUTICALS ANNOUNCES MEXICAN AUTHORIZATION OF VIRAZOLE ANTIVIRAL CREAM FOR HERPES
SPI PHARMACEUTICALS INTRODUCES HEART DRUG IN MEXICO
SPI PHARMACEUTICALS INTRODUCES HEART DRUG IN MEXICO
ICN PHARMACEUTICALS ANNOUNCES YEAR-END RESULTS
SPI PHARMACEUTICALS REPORTS FIRST QUARTER SALES AND NET INCOME
SPI PHARMACEUTICALS INTRODUCES TREATMENT FOR OSTEOPOROSIS IN MEXICO

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters